We are live on
!
Find out more
AACP
Advantage Alpha Capital Partners Portfolio holdings
AUM
$332M
1-Year Est. Return
12.78%
This Fund
S&P 500
This Quarter
Est. Return
+8.8%
1 Year Est. Return
+12.78%
3 Year Est. Return
+79.23%
5 Year Est. Return
+110.24%
10 Year Est. Return
–
AUM
$332M
AUM Growth
-$39.1M
(-11%)
Cap. Flow
-$62.1M
Cap. Flow
% of AUM
-18.72%
Top 10 Holdings %
Top 10 Hldgs %
18.07%
Holding
140
New
21
Increased
26
Reduced
83
Closed
10
Avg Time Held
6.2
quarters
Top 10 Avg Time Held
0.8
quarters
Top 20 Avg Time Held
1.4
quarters
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Harrow
HROW
|
+$4.2M |
| 2 |
Transcat
TRNS
|
+$3.76M |
| 3 |
Ryman Hospitality Properties
RHP
|
+$3.16M |
| 4 |
Universal Technical Institute
UTI
|
+$3M |
| 5 |
Waystar Holding Corp
WAY
|
+$2.93M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Ceco Environmental
CECO
|
+$6.18M |
| 2 |
SharkNinja
SN
|
+$4.32M |
| 3 |
Workiva
WK
|
+$4.31M |
| 4 |
Magnite
MGNI
|
+$4.3M |
| 5 |
FTAI Aviation
FTAI
|
+$4.01M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Industrials | 35.84% |
| 2 | Technology | 18.8% |
| 3 | Healthcare | 15.52% |
| 4 | Consumer Discretionary | 10.94% |
| 5 | Financials | 7.54% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
101
Riot Platforms
RIOT
$6.18B
| $647K | 0.19% |
33,990
-6,912
| -17% | -$95.7K |
2024 Q4
3 quarters
|
|
102
Halozyme
HALO
$12.6B
| $621K | 0.19% |
8,466
-1,567
| -16% | -$104K |
2023 Q4
7 quarters
|
|
103
ANI Pharmaceuticals
ANIP
$1.69B
| $582K | 0.18% |
6,354
-1,598
| -20% | -$130K |
2024 Q3
4 quarters
|
|
104
Veracyte
VCYT
$3.54B
| $544K | 0.16% |
15,859
-3,264
| -17% | -$93.6K |
2023 Q4
7 quarters
|
|
105
ADMA Biologics
ADMA
$2.28B
| $498K | 0.15% |
33,943
-9,875
| -23% | -$169K |
2024 Q1
6 quarters
|
|
106
CleanSpark
CLSK
$2.65B
| $434K | 0.13% |
29,926
-6,827
| -19% | -$77K |
2024 Q4
3 quarters
|
|
107
Alkermes
ALKS
$6.75B
| $424K | 0.13% |
14,122
-3,200
| -18% | -$90.2K |
2023 Q4
7 quarters
|
|
108
Krystal Biotech
KRYS
$9.83B
| $421K | 0.13% |
2,387
-507
| -18% | -$75.9K |
2025 Q1
2 quarters
|
|
109
TG Therapeutics
TGTX
$8.46B
| $419K | 0.13% |
11,598
-2,716
| -19% | -$89.5K |
2024 Q2
5 quarters
|
|
110
Arrowhead Research
ARWR
$8.58B
| $406K | 0.12% |
11,780
-1,158
| -9% | -$25.5K |
2025 Q2
1 quarter
|
|
111
Emergent Biosolutions
EBS
$358M
| $405K | 0.12% |
+45,936
| New | +$357K |
2025 Q3
0 quarters
|
|
112
Stoke Therapeutics
STOK
$1.56B
| $398K | 0.12% |
16,941
-947
| -5% | -$16.2K |
2025 Q2
1 quarter
|
|
113
MiMedx Group
MDXG
$705M
| $396K | 0.12% |
56,727
-9,397
| -14% | -$65.3K |
2023 Q4
7 quarters
|
|
114
Protagonist Therapeutics
PTGX
$9.37B
| $386K | 0.12% |
5,804
-1,168
| -17% | -$66.4K |
2024 Q3
4 quarters
|
|
115
Kura Oncology
KURA
$925M
| $380K | 0.11% |
+42,958
| New | +$306K |
2025 Q3
0 quarters
|
|
116
Rigel Pharmaceuticals
RIGL
$912M
| $334K | 0.1% |
+11,804
| New | +$353K |
2025 Q3
0 quarters
|
|
117
CareDx
CDNA
$3.27B
| $308K | 0.09% |
+21,164
| New | +$302K |
2025 Q3
0 quarters
|
|
118
Keros Therapeutics
KROS
$230M
| $286K | 0.09% |
+18,059
| New | +$267K |
2025 Q3
0 quarters
|
|
119
Hut 8
HUT
$10.5B
| $275K | 0.08% |
+7,898
| New | +$201K |
2025 Q3
0 quarters
|
|
120
DELISTED
Catalyst Pharmaceutical
CPRX
| $262K | 0.08% |
13,313
-2,887
| -18% | -$59.4K |
2024 Q2
5 quarters
|
|
121
DELISTED
Dynavax Technologies
DVAX
| $257K | 0.08% |
25,892
-5,266
| -17% | -$54.8K |
2023 Q4
7 quarters
|
|
122
The Bancorp
TBBK
$2B
| $242K | 0.07% |
+3,226
| New | +$225K |
2025 Q3
0 quarters
|
|
123
Aurinia Pharmaceuticals
AUPH
$2.2B
| $230K | 0.07% |
20,849
-3,230
| -13% | -$35.3K |
2025 Q2
1 quarter
|
|
124
Acadia Pharmaceuticals
ACAD
$3.34B
| $227K | 0.07% |
10,623
-2,020
| -16% | -$47.8K |
2024 Q2
5 quarters
|
|
125
Marathon Digital Holdings
MARA
$3.65B
| $221K | 0.07% |
12,094
-2,975
| -20% | -$50.1K |
2024 Q4
3 quarters
|
|
Similar funds
CPA
PAWA
EE
GB
SC
SFG
PA
BCCM
Advantage Alpha Capital Partners's Q3 2025 Portfolio in Review
As of Q3 2025, Advantage Alpha Capital Partners held 140 positions worth $332M, down 11% from $371M the previous quarter. Its ten largest holdings account for 18% of the portfolio.
Advantage Alpha Capital Partners withdrew a net $62.1M in Q3 2025, closing 10 positions and reducing 83 holdings. Its most notable exit was Boot Barn, an estimated $3.52M position sold in full.
By sector, the portfolio is most concentrated in Industrials at 36% of assets, down from 36% a quarter earlier, followed by Technology and Healthcare.
Against the trend, Advantage Alpha Capital Partners opened a new position in Harrow worth $5.37M.
- Advantage Alpha Capital Partners's largest Q3 2025 buy was Harrow: 111,553 shares worth $5.37M.
- Advantage Alpha Capital Partners added most to Casella Waste Systems in Q3 2025, an estimated $1.96M increase.
- Advantage Alpha Capital Partners's biggest Q3 2025 reduction was Ceco Environmental, cutting an estimated $6.18M.
- Advantage Alpha Capital Partners fully exited Boot Barn in Q3 2025, selling an estimated $3.52M.
- Advantage Alpha Capital Partners's ten largest holdings make up 18% of its $332M portfolio in Q3 2025.
- Advantage Alpha Capital Partners opened 21 new positions and closed 10 in Q3 2025.
- Advantage Alpha Capital Partners's portfolio value fell 11% quarter-over-quarter to $332M.
Based on Advantage Alpha Capital Partners's 13F filing for Q3 2025, filed 12 Nov 2025.